The lipid-modifying agents market, which had seen a dramatic decline over the past decade, is now set for a spectacular revival, driven by the innovating therapies Leqvio (inclisiran) from Swiss pharma giant Novartis (NOVN: VX) and Repatha (evolocumab) from US biotech Amgen 5 July 2024
The US Food and Drug Administration (FDA) has approved Swiss Pharma giant Roche’s (ROG: SIX) Vabysmo (faricimab) 6.0mg single-dose prefilled syringe (PFS) 5 July 2024
In a filing with the US Securities and Exchange Commission (SEC), Pieris Pharmaceuticals (Nasdaq: PIRS) has notified investors that Servier Laboratories is pulling the plug on the firms’ cancer collaboration. 5 July 2024
Global biotechnology firm CSL Behring (ASX: CSL) has announced that two patients with hemophilia B have been treated with the gene therapy Hemgenix (etranacogene dezaparvovec). 5 July 2024
The global recombinant proteins market is projected to grow from $132 billion in 2023 to $203 billion by 2029, according to a recent BCC Research study. 4 July 2024
US biotech Moderna has received a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. 4 July 2024
British drugmaker GSK (LSE: GSK) and Germany's CureVac (Nasdaq: CVAC) have announced a restructuring of their collaboration into a new licensing agreement. 4 July 2024
LenioBio, a German biotech company focused on cell-free protein production, and UK-based enzymatic DNA production Touchlight have announced a supply agreement. 3 July 2024
The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for certain adults with uncontrolled chronic obstructive pulmonary disease (COPD). 3 July 2024
Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
The UK Bioindustry Association (BIA) has joined the European Biosolutions Coalition, an initiative established by several industry organisations to elevate the prominence of biosolutions on Europe’s agenda. 2 July 2024
Amylyx Pharmaceuticals (Nasdaq: AMLX) has acquired the rights to Eiger Biopharmaceuticals’ (Nasdaq: EIGR) experimental drug avexitide for $35.1 million. 2 July 2024
Shares in TRACON Pharmaceuticals have fallen by a third, after the San Diego-based firm announced the termination of work on its candidate envafolimab. 2 July 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.